Delivering the ADC Promise
What challenges do CDMOs face when manufacturing antibody-drug conjugates?
Maryam Mahdi, John Fowler | | Quick Read
With companies seeking external support for antibody-drug conjugate development and manufacturing, CDMOs are playing an increasingly integral role in their success story. Piramal Pharma Solutions – an early adopter of ADC manufacturing capabilities – is one such actor. Here, John Fowler, COO at Piramal Pharma Solutions, discusses the promise – and the challenges – of ADCs.
“With 40 ADCs in clinical trials, there’s a great deal to be excited about when it comes to this class of drugs,” says Fowler. “They have the potential to change not only the way we treat cancer, but a variety of disease indications. And that’s why three of our clients have been able to skip phase III and are ready to apply for INDs.”
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.